Biomarkers and methods for treating nsclc

A method for selecting a therapy for a subject with NSCLC, the method comprising:

• (a) determining the level of CD73 in a sample of the subject, and
• (b) evaluating whether the subject is likely to respond to or benefit from a combination treatment of a CD73 antagonist and a PD1/PD-L1 antagonist based on the level of CD73,
• (c) selecting the combination treatment for the subject when the subject is determined as likely to respond to or benefit from the combination treatment.

A method for treating a subject with NSCLC, comprising administering a CD73 antagonist and a PD1/PD-L1 antagonist to a subject with NSCLC having a level of CD73 in a sample indicating as likely to respond to or benefit from a combination treatment of the CD73 antagonist and the PD1/PD-L1 antagonist.

A method for predicting responsiveness of a subject with NSCLC to a combination treatment of a CD73 antagonist and a PD1/PD-L1 antagonist, comprising:

• (a) determining the level of CD73 in a sample of the subject,
• (b) evaluating whether the subject is likely to respond to or benefit from the combination treatment based on the level of CD73, and
• (c) providing a recommendation of the combination treatment to the subject when the subject is determined as likely to respond to or benefit from the combination treatment.

A method for identifying a subject with NSCLC as more likely to respond to or benefit from a combination treatment of a CD73 antagonist and a PD1/PD-L1 antagonist than a reference patient, comprising:

• (a) determining the level of CD73 in a sample of the subject, wherein an increase of the level of CD73 in the sample relative to that in a reference sample from the reference patient indicates that the subject is more likely to respond to or benefit from the combination treatment than the reference patient, and
• (b) providing a recommendation that the subject will be more likely to respond to or benefit from the combination treatment than the reference patient.

A method for predicting responsiveness of a subject with NSCLC to a combination treatment of a CD73 antagonist and a PD1/PD-L1 antagonist, comprising:

• (a) determining level of CD73 in a sample of the subject, wherein an increase of CD73 in the sample relative to that in a reference sample from a reference patient indicates that the subject is more likely to respond to or benefit from the combination treatment than the reference patient, and
• (b) providing a recommendation that the subject will have an increased likelihood of being responsive to or benefit from the combination treatment as compared to the reference patient.

Use of a CD73 antagonist and a PD1/PD-L1 antagonist for the manufacture of a medicament for treating a subject with NSCLC having a level of CD73 in a sample indicating as likely to respond to or benefit from a combination treatment of the CD73 antagonist and the PD1/PD-L1 antagonist.

Use of a CD73 antagonist for the manufacture of a medicament for treating a subject with NSCLC having a level of CD73 in a sample indicating as likely to respond to or benefit from a combination treatment of the CD73 antagonist and a PD1/PD-L1 antagonist, wherein the subject is also administered the PD1/PD-L1 antagonist.

Use of a PD1/PD-L1 antagonist for the manufacture of a medicament for treating a subject with NSCLC having a level of CD73 in a sample indicating as likely to respond to or benefit from a combination treatment of a CD73 antagonist and the PD1/PD-L1 antagonist, wherein the subject is also administered the CD73 antagonist.